|
[1]SIROHI B, PHILIP DS, SHRIKHANDE SV.Regorafenib:carving a niche in the crowded therapeutic landscape[J].Expert Rev Anticancer Ther, 2013, 13 (4) :385-393.
|
|
[2]WILHELM SM, DUMAS J, ADNANE L, et al.Regorafenib (BAY73-4506) :a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity[J].Int J Cancer, 2011, 129 (1) :245-255.
|
|
[3]VILLANUEVA MT.Gastrointestinal cancer:regorafenib, the CORRECT way forward or just another GRIDlock?[J].Nat Rev Gastroenterol Hepatol, 2013, 10 (1) :1.
|
|
[4]GROTHEY A, van CUTSEM E, SOBRERO A, et al.Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT) :an international, multicentre, randomised, placebo-controlled, phase 3 trial[J].Lancet, 2013, 381 (9863) :303-312.
|
|
[5]ZAKI K, ASLAM S, EISEN T.Regorafenib (BAY 73-4506) :stromal and oncogenic multikinase inhibitor with potential activity in renal cell carcinoma[J].Curr Oncol Rep, 2013, 15 (2) :91-97.
|
|
[6]DAVIS SL, ECKHARDT SG, MESSERSMITH WA, et al.The development of regorafenib and its current and potential future role in cancer therapy[J].Drugs Today (Barc) , 2013, 49 (2) :105-115.
|
|
[7]DEMETRI GD, REICHARDT P, KANG YK, et al.Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID) :an international, multicentre, randomised, placebo-controlled, phase 3 trial[J].Lancet, 2013, 381 (9863) :295-302.
|
|
[8]MROSS K, FROST A, STEINBILD S, et al.A phase I dose-escalation study of regorafenib (BAY 73-4506) , an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors[J].Clin Cancer Res, 2012, 18 (9) :2658-2667.
|
|
[9]SUNAKAWA Y, FURUSE J, OKUSAKA T, et al.Regorafenib in Japanese patients with solid tumors:phase I study of safety, efficacy, and pharmacokinetics[J].Invest New Drugs, 2013, 32 (1) :104-112.
|
|
[10]SHIMIZU T, TOLCHER AW, PATNAIK A, et al.Phase I doseescalation study of continuously administered regorafenib (BAY 73-4506) , an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors[J].J Clin Oncol, 2010, 28 (Suppl 15) :3035-2025.
|
|
[11]FINN RS, BLUMENSCHEIN GR, TOLCHER AW, et al.Continuous-dose regorafenib (REG) in hepatocellular carcinoma (HCC) :Phase I safety and pharmacokinetic (PK) study[J].J Clin Oncol, 2013, 31 (Suppl 4) :300.
|
|
[12]GEORGE S, WANG Q, HEINRICH MC, et al.Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib:a multicenter phase II trial[J].J Clin Oncol, 2012, 30 (19) :2401-2407.
|
|
[13]EISEN T, JOENSUU H, NATHAN PD, et al.Regorafenib for patients with previously untreated metastatic or unresectable renalcell carcinoma:a single-group phase 2 trial[J].Lancet Oncol, 2012, 13 (10) :1055-1062.
|
|
[14]BRUIX J, TAK WY, GASBARRINI A, et al.Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma:Multicentre, open-label, phase II safety study[J].Eur J Cancer, 2013, 49 (16) :3412-3419.
|
|
[15]CHENG AL, FINN RS, KUDO M, et al.Regorafenib (REG) in patients with hepatocellular carcinoma (HCC) progressing following sorafenib:An ongoing randomized, double-blind, phase III trial[J].J Clin Oncol, 2013, 31 (Suppl 15) :4163.
|
DownLoad: